| Dextroamphetamine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Dextroamphetamine | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Dextroamphetamine | hsa00531 | Glycosaminoglycan degradation | 8.18E-04 | 2 | P15586, P34059 | GNS, GALNS | More | |
| Dextroamphetamine | hsa00532 | Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate | 2.92E-02 | 1 | Q9Y2C2 | UST | More | |
| Dextroamphetamine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | |
| Dextroamphetamine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Dextroamphetamine | hsa00830 | Retinol metabolism | 4.25E-02 | 1 | P00325 | ADH1B | More | |
| Dextroamphetamine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Dextroamphetamine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Dextroamphetamine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | |
| Dextroamphetamine | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Dextroamphetamine | hsa03008 | Ribosome biogenesis in eukaryotes | 2.06E-02 | 2 | Q9NYH9, Q9BVP2 | UTP6, GNL3 | More | |
| Dextroamphetamine | hsa03015 | mRNA surveillance pathway | 1.37E-03 | 6 | Q13362, Q14738, O94913, Q9UBU9, Q9H307, Q13148 | PPP2R5C, PPP2R5D, PCF11, NXF1, PNN, TARDBP | More | |
| Dextroamphetamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Dextroamphetamine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | |
| Dextroamphetamine | hsa04020 | Calcium signaling pathway | 1.39E-02 | 4 | P30679, O15399, P07550, P23634 | GNA15, GRIN2D, ADRB2, ATP2B4 | More | |
| Dextroamphetamine | hsa04071 | Sphingolipid signaling pathway | 8.46E-04 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, GAB2 | More | |
| Dextroamphetamine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Dextroamphetamine | hsa04114 | Oocyte meiosis | 1.25E-03 | 7 | P51812, Q02750, P0DP23, P16298, Q17RY0, Q13362, Q14738 | RPS6KA3, MAP2K1, CALM1, PPP3CB, CPEB4, PPP2R5C, PPP2R5D | More | |
| Dextroamphetamine | hsa04120 | Ubiquitin mediated proteolysis | 3.42E-03 | 6 | Q14145, Q13042, P30260, Q13191, P62837, Q15751 | KEAP1, CDC16, CDC27, CBLB, UBE2D2, HERC1 | More | |
| Dextroamphetamine | hsa04142 | Lysosome | 1.14E-02 | 3 | P43234, P15586, P34059 | CTSO, GNS, GALNS | More | |
| Dextroamphetamine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | |
| Dextroamphetamine | hsa04152 | AMPK signaling pathway | 1.83E-02 | 3 | Q96RR4, Q13362, Q14738 | CAMKK2, PPP2R5C, PPP2R5D | More | |
| Dextroamphetamine | hsa04210 | Apoptosis | 9.18E-03 | 4 | P04637, P24522, P43234, P63261 | TP53, GADD45A, CTSO, ACTG1 | More | |
| Dextroamphetamine | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Dextroamphetamine | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.75E-03 | 6 | P07550, P22694, P18848, Q13362, Q14738, P0DP23 | ADRB2, PRKACB, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | |
| Dextroamphetamine | hsa04340 | Hedgehog signaling pathway | 1.80E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | |
| Dextroamphetamine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | |
| Dextroamphetamine | hsa04610 | Complement and coagulation cascades | 2.78E-03 | 1 | P0C0L4 | C4A | More | |
| Dextroamphetamine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Dextroamphetamine | hsa04613 | Neutrophil extracellular trap formation | 4.20E-02 | 5 | P04908, Q93077, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Dextroamphetamine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.52E-05 | 10 | P16298, P50591, P01375, P20963, Q02750, Q13241, P26718, P26717, Q14953, P26715 | PPP3CB, TNFSF10, TNF, CD247, MAP2K1, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Dextroamphetamine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | |
| Dextroamphetamine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Dextroamphetamine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Dextroamphetamine | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
| Dextroamphetamine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Dextroamphetamine | hsa04728 | Dopaminergic synapse | 2.66E-02 | 3 | Q13362, Q14738, P0DP23 | PPP2R5C, PPP2R5D, CALM1 | More | |
| Dextroamphetamine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Dextroamphetamine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Dextroamphetamine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Dextroamphetamine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | |
| Dextroamphetamine | hsa04921 | Oxytocin signaling pathway | 3.13E-02 | 3 | P0DP23, Q96RR4, Q13469 | CALM1, CAMKK2, NFATC2 | More | |
| Dextroamphetamine | hsa04924 | Renin secretion | 3.43E-03 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
| Dextroamphetamine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Dextroamphetamine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Dextroamphetamine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
| Dextroamphetamine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Dextroamphetamine | hsa04966 | Collecting duct acid secretion | 1.68E-02 | 2 | P02730, P00918 | SLC4A1, CA2 | More | |
| Dextroamphetamine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Dextroamphetamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | |
| Dextroamphetamine | hsa04979 | Cholesterol metabolism | 1.61E-02 | 2 | P38571, P61916 | LIPA, NPC2 | More | |
| Dextroamphetamine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Dextroamphetamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
| Dextroamphetamine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Dextroamphetamine | hsa05033 | Nicotine addiction | 1.22E-02 | 2 | P28472, O15399 | GABRB3, GRIN2D | More | |
| Dextroamphetamine | hsa05133 | Pertussis | 4.94E-02 | 1 | P0C0L4 | C4A | More | |
| Dextroamphetamine | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Dextroamphetamine | hsa05144 | Malaria | 3.02E-03 | 4 | O60603, P01375, P35443, P26718 | TLR2, TNF, THBS4, KLRK1 | More | |
| Dextroamphetamine | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Dextroamphetamine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Dextroamphetamine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.39E-03 | 7 | P23458, P62879, Q13469, P16298, Q02750, P0DP23, P0CG47 | JAK1, GNB2, NFATC2, PPP3CB, MAP2K1, CALM1, UBB | More | |
| Dextroamphetamine | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | |
| Dextroamphetamine | hsa05205 | Proteoglycans in cancer | 4.79E-03 | 8 | P63261, P04637, P14780, P01375, P23588, Q06124, Q13635, P22694 | ACTG1, TP53, MMP9, TNF, EIF4B, PTPN11, PTCH1, PRKACB | More | |
| Dextroamphetamine | hsa05211 | Renal cell carcinoma | 7.75E-03 | 2 | Q06124, Q99814 | PTPN11, EPAS1 | More | |
| Dextroamphetamine | hsa05212 | Pancreatic cancer | 2.33E-03 | 4 | Q15311, P23458, P04637, P24522 | RALBP1, JAK1, TP53, GADD45A | More | |
| Dextroamphetamine | hsa05213 | Endometrial cancer | 2.44E-03 | 4 | O15169, Q02750, P04637, P24522 | AXIN1, MAP2K1, TP53, GADD45A | More | |
| Dextroamphetamine | hsa05214 | Glioma | 2.60E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Dextroamphetamine | hsa05216 | Thyroid cancer | 1.14E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Dextroamphetamine | hsa05217 | Basal cell carcinoma | 2.06E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Dextroamphetamine | hsa05218 | Melanoma | 3.41E-04 | 5 | P09619, Q9GZP0, P04637, Q02750, P24522 | PDGFRB, PDGFD, TP53, MAP2K1, GADD45A | More | |
| Dextroamphetamine | hsa05220 | Chronic myeloid leukemia | 7.90E-03 | 3 | Q06124, P04637, P24522 | PTPN11, TP53, GADD45A | More | |
| Dextroamphetamine | hsa05223 | Non-small cell lung cancer | 3.19E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Dextroamphetamine | hsa05224 | Breast cancer | 4.51E-02 | 2 | P04637, P24522 | TP53, GADD45A | More | |
| Dextroamphetamine | hsa05225 | Hepatocellular carcinoma | 3.30E-02 | 3 | P04637, P24522, P63261 | TP53, GADD45A, ACTG1 | More | |
| Dextroamphetamine | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | |
| Dextroamphetamine | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | |
| Dextroamphetamine | hsa05321 | Inflammatory bowel disease | 3.02E-03 | 4 | O60603, P01375, Q14765, Q9UL17 | TLR2, TNF, STAT4, TBX21 | More | |
| Dextroamphetamine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Dextroamphetamine | hsa05332 | Graft-versus-host disease | 5.46E-05 | 5 | P48023, P10747, P01375, P26715, Q13241 | FASLG, CD28, TNF, KLRC1, KLRD1 | More | |
| Dextroamphetamine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 3.10E-02 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | |
| Dextroamphetamine | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | |
| Dextroamphetamine | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
